Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51201 | 0.76 | FFAR3 (0.41) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| Hydrochloric Acid SCHEMBL8053454 | 0.73 | FFAR3 (0.39) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL104624 | 0.73 | FFAR3 (0.39) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL4882973 | 0.73 | FFAR3 (0.39) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL28746064 | 0.73 | FFAR3 (0.39) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL3673385 | 0.73 | ALDH1A1 (0.39) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL4382923 | 0.73 | FFAR3 (0.39) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL17818653 | 0.73 | FFAR3 (0.39) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL9489101 | 0.73 | FFAR3 (0.39) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| Hydrochloric Acid SCHEMBL808883 | 0.73 | FFAR3 (0.39) | MEN1ALDH1A1CYP1A2THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-6762187-B2 | HETEROCYCLIC NITROGEN COMPOUNDS USED AS ENZYME INHIBITORS FOR PROPHYLAXIS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) | MONSANTO COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-20030195227-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103311-A1 | Retroviral protease inhibitors | PREP, DNPEP, SERPINB1 | MEN1 4153/4885ALDH1A1 2859/4885CYP1A2 3513/4885 |
| US-20030195227-A1 | Retroviral protease inhibitors | MME, PREP, TMPRSS15 | MEN1 3106/4885ALDH1A1 2763/4885CYP1A2 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.